Zobrazeno 1 - 10
of 288
pro vyhledávání: '"Non -Hodgkin lymphoma (NHL)"'
Autor:
Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CA
Externí odkaz:
https://doaj.org/article/7841086f48d141fcacd16214fbafb379
Autor:
Danis URSU, Eva GUDUMAC, Jana BERNIC, Andrei TÎBÎRNĂ, Silvia RAILEAN, Roman LUPAN, Natalia LISITSA, Rodica GOLBAN
Publikováno v:
Buletinul Academiei de Ştiinţe a Moldovei: Ştiinţe Medicale, Vol 76, Iss 2, Pp 36-41 (2023)
Thisarticle discusses various aspects of pediatric lymphadenopathy, focusing on Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). It outlines common etiologies, diagnostic techniques, and key characteristics of differ- ent lymphoma subtypes. HL i
Externí odkaz:
https://doaj.org/article/d13f7b2ae6a34c0c83c4ef5ff39ba6d6
Autor:
Fulvio Massaro, Fabio Andreozzi, Tom Abrassart, Julie Castiaux, Hanne Massa, Ornella Rizzo, Marie Vercruyssen
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 977 (2024)
Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impac
Externí odkaz:
https://doaj.org/article/e8516ff12f8e443496a629d4e617bbbd
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S14- (2023)
Background: Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma (NHL) originating from B-lymphocytes. It is characterized as a slow-growing or indolent lymphoma and is considered a rare disease. The report focuses on a case of MZL diagnose
Externí odkaz:
https://doaj.org/article/9b6e7c5d5d7a4a5b9de7def619bba20f
Autor:
Hastono Ridwansyah, Indra Wijaya, Muhammad Hasan Bashari, Achmad Hussein Sundawa Kartamihardja, Bethy Suryawathy Hernowo
Publikováno v:
Biomolecules & Biomedicine, Vol 23, Iss 5 (2023)
B-cell non-Hodgkin lymphoma (B-NHL) is a lymphoid malignancy derived from B-cells that remains difficult to treat. Moreover, relapses and refractory cases are common. Abnormalities in epigenetic mechanisms, such as imbalanced histone acetylation affe
Externí odkaz:
https://doaj.org/article/dfe1cb5784014dff8c4998ed01a9e092
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
ImmunoMedicine, Vol 2, Iss 1, Pp n/a-n/a (2022)
Abstract Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CA
Externí odkaz:
https://doaj.org/article/32939fc747924d238e8275448fc36a1f
Autor:
Khansa Saleem, Muhammad Ilyas, Saad Razzaq, Fahad Maqbool, Qaiser Abbas, Aneem Abdullah, Abu Bakar Shahid
Publikováno v:
Proceedings, Vol 35, Iss 1, Pp 7-11 (2021)
Introduction: Acute lymphoblastic leukemia (ALL) is a malignancy of the white blood cells and lymphoid lines of hematopoietic cells in the blood and bone marrow while lymphomas mostly involve the lymph nodes. This study showed the response rate of AL
Externí odkaz:
https://doaj.org/article/147a8919e7b54f5497478f89ce90324f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and mortality, is a common and well-known complication that occurs during the treatment of non-Hodgkin lymphoma (NHL) patients with current or past exposure to HBV infect
Externí odkaz:
https://doaj.org/article/e21cf03d5f1c49a09ee8c2c96b373417